• Mon news: Novartis in $745M radiopharma pact. Novo launches Wegovy in China. COVID-era telehealth prescribing extended. Hims & Hers GLP-1 tracker. Promising Gilead liver disease trial. See more on our front page

AGN, ACT, FRX Frankenstein Pharma here

















Being a freak is very good if your left standing after the dust settles - sadly for Allergan folks no Pfizer people EVER get let go in these takeovers.

I wouldn't be so sure this time. People will be let go for sure, but if Saunders is CEO (and there is a good chance at this) I wouldn't except it to be just as simple as all PFE reps stay and AGN leave. Will be done by business unit and what ever is cheaper and easier to do. All I am saying is that when you deal with Saunders, expect the unexpected and do not use any prior acquisition as your reference point.